The earnings call highlighted record-breaking revenue and growth, strong product performance, and successful FDA clearance for a new product, indicating a positive outlook. However, challenges such as declining international sales and operational inefficiencies during the facility transition present some concerns. Overall, the positive aspects significantly outweigh the negatives.

Company Guidance

During the IRADIMED CORPORATION's second-quarter 2025 earnings call, the company provided updated guidance indicating strong growth expectations. For the third quarter of 2025, they anticipate revenue between $20.5 million and $20.9 million, reflecting a 12% to 14% increase over the same period in 2024. They also expect GAAP diluted earnings per share to range from $0.41 to $0.45, with non-GAAP EPS projected between $0.45 and $0.49. For the full year of 2025, IRADIMED has increased its revenue guidance to $80 million to $82.5 million, representing a 9% to 13% growth over 2024's $73.2 million revenue. The GAAP diluted EPS is expected to be between $1.60 and $1.70, while non-GAAP EPS is projected to be between $1.76 and $1.86. This updated guidance takes into account approximately $2.6 million in stock-related compensation expense for the year. The company remains committed to delivering shareholder value with a $0.17 per share quarterly dividend declared for Q3 2025.

Record-Breaking Revenue and Growth

Achieved revenue of $20.4 million in Q2 2025, a 14% increase over the same period last year, marking the 16th consecutive quarter of record revenues. GAAP diluted earnings per share increased 18% from Q2 of 2024.

Strong Product Performance

MRI IV pump systems contributed $8.2 million, up 19% year-over-year, and patient vital signs monitoring systems contributed $5.9 million, up 9%.

FDA Clearance for New Product

The FDA cleared the new 3870 IV pump systems for distribution, marking a significant milestone for the company.

Positive Financial Guidance

For Q3 2025, expected revenue of $20.5 million to $20.9 million, representing 12% to 14% growth over Q3 2024. For the full year 2025, revenue is expected to be $80 million to $82.5 million, up from prior guidance of $78 million to $82 million.

Strong Cash Flow and Financial Position

Cash and cash equivalents of $53 million, with a strong cash flow from operations of $7.7 million for the quarter, up 17% from Q2 2024.

Iradimed (IRMD) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

IRMD Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 31, 2025	2025 (Q3)	0.46 / -	0.43	―	―	―
Aug 01, 2025	2025 (Q2)	0.43 / 0.49	0.42	16.67% (+0.07)	―
May 05, 2025	2025 (Q1)	0.41 / 0.42	0.36	16.67% (+0.06)	―
Feb 13, 2025	2024 (Q4)	0.44 / 0.44	0.39	12.82% (+0.05)	―
Oct 31, 2024	2024 (Q3)	0.41 / 0.43	0.43	0.00% (0.00)
Aug 01, 2024	2024 (Q2)	0.36 / 0.42	0.36	16.67% (+0.06)	―
May 02, 2024	2024 (Q1)	0.34 / 0.36	0.3	20.00% (+0.06)	―
Feb 08, 2024	2023 (Q4)	0.38 / 0.39	0.32	21.88% (+0.07)	―
Nov 03, 2023	2023 (Q3)	0.36 / 0.43	0.29	48.28% (+0.14)	―
Aug 03, 2023	2023 (Q2)	0.31 / 0.36	0.26	38.46% (+0.10)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

IRMD Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 01, 2025	$58.20	$66.01	+13.42%
May 05, 2025	$53.17	$52.01	-2.18%
Feb 13, 2025	$59.96	$54.93	-8.39%
Oct 31, 2024	$52.34	$48.71	-6.94%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Iradimed Corp (IRMD) report earnings?

Iradimed Corp (IRMD) is schdueled to report earning on Oct 31, 2025, Before Open (Confirmed).

What is Iradimed Corp (IRMD) earnings time?

Iradimed Corp (IRMD) earnings time is at Oct 31, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is IRMD EPS forecast?

IRMD EPS forecast for the fiscal quarter 2025 (Q3) is 0.46.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing